Tim Funnell
Partner @ Monograph Capital
Boston, United States
Tim Funnell is a Series A investor at Monograph Capital in Boston focused on Medical and Health Care. Tim Funnell is the Partner of Monograph Capital. He previously worked at MiroBio Ltd as a Founding team: VP, Operations. Tim Funnell attended the University of Oxford.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Tim Funnell invests in
Stages Tim Funnell invests in
Countries Tim Funnell invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (20%)
- Health Care 1 (20%)
- Therapeutics 1 (20%)
- Biotechnology 1 (20%)
- Information Technology 1 (20%)
Country
- United Kingdom 3 (60%)
- United States 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Elevara Medicine
|
Elevara Medicines addresses a basic issue in rheumatoid arthritis (RA): individuals who fail to achieve disease remission using immune-targeted therapies. Elevara Medicines intends to breach the efficacy barrier that patients face with current immunosuppressive medications. | $70M / Series A / Oct 22, 2025 | |
Maxion Therapeutics
|
Maxion Therapeutics helps in learning transformative therapies. It uses this technology to deliver long-acting, safe, and effective medications against previously inaccessible targets. | $75.3M / Series A / Mar 17, 2025 | |
Ouro Medicines
|
Ouroboros Medicines is a biotechnology company that specializes in immunology and focuses on treating long-term immune-mediated illnesses. The company addresses chronic immune-mediated conditions directly by integrating scientific knowledge, a proven history of progressing cell-depleting treatments through clinical trials, and a strong pipeline. | $120M / Series A / Jan 10, 2025 | |
|
Maxion Therapeutics
|
Maxion Therapeutics helps in learning transformative therapies. It uses this technology to deliver long-acting, safe, and effective medications against previously inaccessible targets. | $15.6M / Series A / Feb 15, 2023 | |
AviadoBio
|
AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK DementiaResearch Institute. | $77.9M / Series A / Dec 02, 2021 |
Co-Investors
About Monograph Capital
Monograph Capital is a life sciences venture firm. We find and fund groundbreaking life sciences companies to transform promising science into real, life-changing treatments for people across the world.
Monograph Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Charles Conn
Co-founder
|
|||
|
Tim Funnell
Partner
|
|||
Bonnie van Wilgenburg
Principal
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Tim Funnell invest in?
Tim Funnell invests primarily in Medical, Health Care and Therapeutics startups, most often at Series A stage. Most of the 5 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Tim Funnell?
Public channels for Tim Funnell include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Tim Funnell last invest?
The most recent investment recorded for Tim Funnell closed in Oct 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
